European Besremi legal tussle continues - MPN Voice

MPN Voice

10,887 members15,204 posts

European Besremi legal tussle continues

Manouche profile image
12 Replies

« In the latest chapter in an ongoing contract dispute between AOP Orphan Pharmaceuticals GmbH and Pharmaessentia Corp., the German Federal Court of Justice this week set aside the €143 million (US$162.8 million) in damages awarded to AOP, citing procedural flaws in quantifying the product supply and damages »bioworld.com/articles/51622...

Written by
Manouche profile image
Manouche
To view profiles and participate in discussions please or .
12 Replies
hunter5582 profile image
hunter5582

Do you know precisely what "procedural flaws in quantifying the product supply and damages" refers to? It would be interesting to know more about what is going on.

Manouche profile image
Manouche in reply tohunter5582

It would be interesting to know. Unfortunately I can’t access to the full article.

in reply toManouche

This was posted a week or so on the forum another thread

aop-health.com/global_en/ou...

Manouche profile image
Manouche in reply to

It says « Vienna, 25th March 2021 »

in reply toManouche

Yes your right. But it’s the same topic. Damages are same. AOP headquarters are in Vienna. Thinking background?

Manouche profile image
Manouche in reply to

« German Federal Court of Justice Upholds AOP's License Rights in Ropeginterferon and PEC's Liability for Damages.On Monday February 14, 2022 the German Federal Court of Justice decided on PEC's challenge of the award in the dispute between AOP Orphan Pharmaceuticals GmbH and PharmaEssentia Corporation. The decision confirmed that PharmaEssentia's attempts to deprive AOP of its license rights in Ropeginterferon alpha-2b have failed. It upholds the award finding the License Agreement valid and PharmaEssentia liable for certain damages and dismissing all PharmaEssentia's claims against AOP. However, it finds procedural flaws with respect to product supply and damage quantification, impacting the damages awarded. AOP will continue BESREMi® sales and claim all damages ».

businesswire.com/news/home/....

pepper- profile image
pepper- in reply tohunter5582

Here is a comprehensive case analysis. Lot's of legalese: casetext.com/case/aop-orpha...

Joey1025 profile image
Joey1025 in reply tohunter5582

Hi hunter, I just came across this old post. This blog post I recently found provides a easy-readable summary of the German court's decision.

hanefeld-legal.com/blog/bgh...

It seems the court considered that the arbitral tribunal explained sufficiently that Pharma Essential intentionally breached the contract with AOP for one claim, but failed to explain why for another claim the breach was also intentional. Also some misreading of the Pharma Essential's objection to the amount of damages were noted by the court.

EPguy profile image
EPguy

My take is PharmaEssentia (PEC) remains the equivalent of guilty on all counts. PEC had << request(ed) again that the award be set aside>> This set-aside is not going to happen but the damages may be adjusted to a relatively minor extent.

pepper- profile image
pepper-

Complete case analysis: casetext.com/case/aop-orpha...

hunter5582 profile image
hunter5582 in reply topepper-

What a bunch of legal mumbo-jumbo!

taurussy profile image
taurussy

If I have any difficulties in the process of doing business, most often I turn to lawyers for help. But nevertheless, I believe that it's necessary to sort out such moments on my own with the help of blogs such as this one at the link pandawaiver.com/blog/. This is a blog by Pandadoc whose products I often use for working with documents.

Not what you're looking for?

You may also like...

Besremi Supply Security Issues??

Sorry, guys - this could very much just be me being too paranoid - but I would like to ask if...
Joey1025 profile image

ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi®

«We are relieved that the ICC ruling compensates AOP Orphan now for the delay in getting BESREMi®...
Manouche profile image

Pen injector for Besremi in the US

Today I saw news on PharmaEssentia's website stating that they have applied in the United States to...
Joey1025 profile image

Besremi decision time

Getting to the point where I need to make a decision whether to start Besremi. Just had a CBC...
wateron profile image

AOP Orphan announces 5-year results on BESREMi® in PV at the ASH Annual Meeting 2020

Besremi showed clear advantages in efficacy and safety/tolerability versus best-available-treatment...
Manouche profile image

Moderation team

Debinha profile image
DebinhaAdministrator
Mazcd profile image
MazcdPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.